Please assess the completion status of the following clinical trial:

Trial Title: Japanese Phase 1 Trial of Sym004 in Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese male or female subjects aged greater than or equal to 20 years at the time of informed consent signature~* Histologically or cytologically confirmed cancer~* Refractory or recurrent advanced late stage solid tumors without available therapeutic options which are likely to provide patient benefit (failure and/or intolerance to standard anti-cancer therapy)~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Life expectancy of at least 3 months~* Written informed consent given before any trial-related activities are carried out~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Subjects with symptomatic brain metastases~* Subjects who received total resection or irradiation of the target lesion~* Received any of the following medications within 4 weeks before the first administration of Sym004 at Week 1: cytotoxic or cytostatic anti-cancer therapy, antibody therapy, tyrosine kinase inhibitors, and any investigational agent~* Received vaccine therapy as anticancer treatment within 12 weeks before the first administration of Sym004 at Week 1~* Diarrhea of greater than Grade 1 according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 (v4.03)~* Skin manifestation of greater than Grade 1 according to NCI-CTCAE (v4.03)~* Magnesium of less than 0.9 milligram per deciliter (mg/dL)~* Abnormal organ or bone marrow function as defined in the protocol~* Received immunosuppressive agents (including systemic corticosteroids used at doses above 20 milligram per day (mg/day) of prednisolone or equivalent) within 4 weeks before the first administration of Sym004 at Week 1~* Active severe infection, any other concurrent disease or medical conditions that are deemed to interfere with the conduct of the trial as judged by the Investigator~* Known human immunodeficiency virus (HIV) positive, active Hepatitis B or C, or uncontrolled allergic conditions or allergy to Sym004 or its components~* Clinically significant cardiac disease or concurrent, uncontrolled medical condition~* Known previous Grade 3 to 4 infusion-related reactions, according to NCI-CTCAE (v4.03), with chimeric monoclonal antibodies~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sym004 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).